Literature DB >> 25888269

In reply.

Richard J Auchus1, Margaret K Yu2, Suzanne Nguyen3, Suneel D Mundle4.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25888269      PMCID： PMC4425393          DOI： 10.1634/theoncologist.2015-0010

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  9 in total

Review 1.  Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.

Authors:  Richard J Auchus; Margaret K Yu; Suzanne Nguyen; Suneel D Mundle
Journal:  Oncologist       Date:  2014-10-31

2.  Is dexamethasone a better partner for abiraterone than prednisolone?

Authors:  Omer Dizdar
Journal:  Oncologist       Date:  2015-04-17

3.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

4.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono
Journal:  Lancet Oncol       Date:  2012-09-18       Impact factor: 41.316

5.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Charles J Ryan; Matthew R Smith; Karim Fizazi; Fred Saad; Peter F A Mulders; Cora N Sternberg; Kurt Miller; Christopher J Logothetis; Neal D Shore; Eric J Small; Joan Carles; Thomas W Flaig; Mary-Ellen Taplin; Celestia S Higano; Paul de Souza; Johann S de Bono; Thomas W Griffin; Peter De Porre; Margaret K Yu; Youn C Park; Jinhui Li; Thian Kheoh; Vahid Naini; Arturo Molina; Dana E Rathkopf
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

6.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

7.  Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

Authors:  Dana E Rathkopf; Matthew R Smith; Johann S de Bono; Christopher J Logothetis; Neal D Shore; Paul de Souza; Karim Fizazi; Peter F A Mulders; Paul Mainwaring; John D Hainsworth; Tomasz M Beer; Scott North; Yves Fradet; Hendrik Van Poppel; Joan Carles; Thomas W Flaig; Eleni Efstathiou; Evan Y Yu; Celestia S Higano; Mary-Ellen Taplin; Thomas W Griffin; Mary B Todd; Margaret K Yu; Youn C Park; Thian Kheoh; Eric J Small; Howard I Scher; Arturo Molina; Charles J Ryan; Fred Saad
Journal:  Eur Urol       Date:  2014-03-06       Impact factor: 20.096

8.  A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.

Authors:  Ramachandran Venkitaraman; David Lorente; Vedang Murthy; Karen Thomas; Lydia Parker; Ruth Ahiabor; David Dearnaley; Robert Huddart; Johann De Bono; Chris Parker
Journal:  Eur Urol       Date:  2014-10-16       Impact factor: 20.096

9.  Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.

Authors:  D Lorente; A Omlin; R Ferraldeschi; C Pezaro; R Perez; J Mateo; A Altavilla; Z Zafeirou; N Tunariu; C Parker; D Dearnaley; S Gillessen; J de Bono; G Attard
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.